Press & Latest News
About Lumosity
Lumosity is a pioneer in cognitive health and digital medicine with a mission of empowering everyone to discover what their mind can do. Lumosity has attracted over 100 million members from 180+ countries, contributing to a dataset of over 8 billion cognitive games played, which serve to support over 100 collaborations with university research groups. Our medical division is at the forefront of developing FDA-cleared digital medicine, such as LumosityRx, a digital therapeutic for adult ADHD. Awarded by the Future of Privacy Forum for Data Stewardship, Lumosity prides itself on supporting the advancement of cognitive research while protecting the privacy of its members.
Media Contact
press@lumoslabs.com- Founded: 2005, launched 2007
- Location: San Francisco, CA
- Games: 40+ on web and mobile
- Users: Over 100 million registered users from 195 countries
- Games played: 8 billion+ games played on web and mobile apps
- Human Cognition Project: 100+ researchers, 130+ peer-reviewed research articles
- Languages: English, Spanish, French, German, Japanese, Korean, Portuguese
Latest News
Lumosity Announces FDA Clearance of LumosityRx, a Prescription Digital Therapeutic for Adults with ADHD
Lumosity today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for LumosityRx, a prescription digital therapeutic (PDT) designed to improve attention in adults with Attention Deficit Hyperactivity Disorder (ADHD), ages 22 to 55.
Read MoreNew Big Data Study Reveals Clear Link Between "Dose" of Brain Training and Improvements in Cognition Across All Ages
A study led by psychologist Allen Osman, PhD, and the research team at Lumos Labs, leverages big data from Lumosity gameplays to shed new light on the impact of cognitive training on cognitive performance.
Read MoreLumos Labs Appoints Neuroscientist Bob Schafer as CEO to Propel Expansion into Digital Medicine
Lumos Labs, makers of Lumosity brain training and leaders in digital health for the brain and cognition, today announced the appointment of Bob Schafer, PhD, as Chief Executive Officer.
Read More